Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

10 Dec 2025

1517.40

0.34%

Cipla Launches Drug For Obesity, Diabetes

NDTV Profit

Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus.

Cipla Ltd. has an average target of 1704.00 from 8 brokers.

Cipla Ltd.

10 Dec 2025

1517.40

0.34%

Company Update

Cipla Ltd - 500087 - Update On Launch Of Yurpeak(r) (Tirzepatide) In India For The Treatment …

BSE India

Update on launch of Yurpeak (Tirzepatide) in India for the treatment of Obesity and Type 2 Diabetes

pdf

Cipla Ltd.

10 Dec 2025

1517.40

0.34%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find attached disclosure on ESG rating

pdf

Cipla Ltd.

04 Dec 2025

1517.40

0.34%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Update on acquisition of securities in Inzpera Healthsciences Limited

pdf

Cipla Ltd.

03 Dec 2025

1517.40

0.34%

Cipla, Stempeutics launch stem cell therapy for knee osteoarthritis

Business Standard

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA

Cipla Ltd. has an average target of 1704.00 from 8 brokers.

Cipla launches Ciplostem cell therapy for Knee Osteoarthritis in India

Business Line | 03 Dec 2025

Cipla Ltd.

01 Dec 2025

1517.40

0.34%

SAST

Cipla Ltd - 500087 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India

pdf

Cipla Ltd.

28 Nov 2025

1517.40

0.34%

Cipla opens lung centre in Delhi

Business Line

Cipla launches a Breathefree Lung Wellness Center in Delhi to enhance lung diagnostics amid rising respiratory diseases and air pollution.

Cipla Ltd. has an average target of 1704.00 from 8 brokers.

Cipla launches India's first integrated lung diagnostics, wellness centre

Business Standard | 28 Nov 2025

Cipla Ltd.

10 Nov 2025

1517.40

0.34%

Novo Nordisk inks collaboration with Emcure, to sell its weightloss and diabetes drug Wegovy

Business Line

The announcement comes just weeks after US company Eli Lilly announced its agreement with Cipla to sell tirzepatide in India,

Cipla Ltd. has an average target of 1704.00 from 8 brokers.

Cipla Ltd.

06 Nov 2025

1517.40

0.34%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication regarding special window for re- lodgement of transfer requests of physical shares

pdf

Cipla Ltd.

04 Nov 2025

1517.40

0.34%

Growth outlook intact despite near-term headwinds

Accumulate: Cipla Ltd.

Target

Deven Choksey

Cipla’s near-to-medium term outlook remains positive, underpinned by strong execution in domestic formulations and a visible ramp-up in complex generics and biosimilars in the U.S. market.

Cipla Ltd. has an average target of 1704.00 from 8 brokers.

Is Cipla Ltd. worth buying?

637 Votes:

Buy 75.82%

Sell 13.66%

Hold 10.52%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf